PIKA rabies vaccine / YS Biopharma - LARVOL DELTA

A Study to Evaluate a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried (clinicaltrials.gov) - P3 | N=4500 | Active, not recruiting | Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd. | Trial primary completion date: Dec 2023 ➔ Mar 2024

Trial primary completion date

A Study to Evaluate a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried (clinicaltrials.gov) - P3 | N=4500 | Active, not recruiting | Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Oct 2024 ➔ Feb 2025 | Initiation date: Dec 2023 ➔ Sep 2023

Enrollment closed • Trial completion date • Trial initiation date

Potential option for rabies post-exposure prophylaxis: New vaccine with PIKA adjuvant against diverse Chinese rabies strains. (PubMed, Vaccine) - "In contrast, the PIKA rabies vaccine exhibited a more significant enhancement in neutralizing antibody levels just 5 days post-vaccination, surpassing the immune response induced by licensed rabies vaccines...Confirmation of the mechanism of action of PIKA was further established by testing it on TLR3-knockout mice, proving that its adjuvant function is dependent on the TLR3 pathway. Taken together, these results indicate that the PIKA vaccine for rabies shows potential as a highly efficacious approach, resulting in a significant enhancement of the efficacy of rabies vaccines."

Journal • CCL2 • IFNG • IL1B • IL6 • TLR3 • TNFA

A Study to Evaluate a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried (clinicaltrials.gov) - P3 | N=4500 | Not yet recruiting | Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd. | Trial completion date: Apr 2024 ➔ Oct 2024 | Initiation date: Apr 2023 ➔ Oct 2023 | Trial primary completion date: Apr 2024 ➔ Oct 2024

Trial completion date • Trial initiation date • Trial primary completion date

A Phase III, Study to Evaluate a PIKA-Adjuvanted Inactivated Rabies Vaccine (clinicaltrials.gov) - P3 | N=4500 | Not yet recruiting | Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd.

New P3 trial